Suven Life gets patent for neuro-degenerative drug
Advertisement
New Delhi: Drug firm Suven Life Sciences has been granted a patent each by Europe, Hong Kong, Japan, Macau, ARIPO and South Korea for a neuro degenerative drug used in the treatment of neuro degenerative diseases.
In a BSE filing today, Suven Life said: "They secured product patents in ARIPO, Europe, Hong Kong, Japan, Macau and South Korea to their New Chemical Entities (NCEs) for CNS therapy."
The patents are valid till 2031, the company added.
In a BSE filing today, Suven Life said: "They secured product patents in ARIPO, Europe, Hong Kong, Japan, Macau and South Korea to their New Chemical Entities (NCEs) for CNS therapy."
The patents are valid till 2031, the company added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.